Electra Therapeutics (ETRA) Registration filing summary

Company overview and business model

• Late clinical-stage biopharmaceutical company developing precision medicines for immune-mediated diseases and cancer, focusing on SIRP-targeted therapies.

• Lead candidate ipsoprubart is a pan-SIRP monoclonal antibody for secondary hemophagocytic lymphohistiocytosis (sHLH) and T/NK cell malignancies.

• ELA822, a SIRPg-specific antibody, targets chronic T cell-mediated immune and inflammatory diseases.

• Proprietary SIRP-targeted antibody library enables expansion into additional indications.

Financial performance and metrics

• Net loss of $61.98 million for 2025 and $48.91 million for the six months ended June 30, 2026.

• Accumulated deficit of $221.9 million as of June 30, 2026.

• Cash, cash equivalents, and marketable securities of $97.7 million as of June 30, 2026.

• Research and development expenses increased 122% year-over-year for the first half of 2026, primarily due to advancement of clinical programs.

Use of proceeds and capital allocation

• Estimated net proceeds of $296.6 million (or $341.9 million if underwriters' option exercised) at $15.00 per share.

• Proceeds allocated to: $220M for ipsoprubart in sHLH, $25M for ipsoprubart in T/NK cell malignancies, $50M for ELA822, and remainder for R&D, working capital, and general corporate purposes.

• Funds expected to support operations into 2029, but not sufficient for full clinical development and commercialization.